ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma.

J Clin Oncol · 2021 · PMC8078325 · PMID 33621109

Europe PMC DOI

hedged sentence

0.0900

closest p · 1.8× alpha

0.0900

boldest claim

The sentences

a positive trendP = .09so close (0.05 < p ≤ 0.1)

Exploratory subgroup analyses of PFS suggested a positive trend in 2-year PFS favoring R2-CHOP ( v placebo/R-CHOP) in patients with IPI ≥ 3 (59% v 50%, P = .09; Fig 3 ), nonbulky disease (73% v 66%, P = .05), and lower baseline creatinine clearance 30 to < 60 mL/min (69% v 45%, P = .03; Fig 4 ).

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.